摘要 |
This invention relates to novel compounds having the structural formula (I) below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. These novel compounds provide a treatment or prophylaxis of anxiety disorders, schizophrenia, cognitive disorders, and/or mood disorders. |
申请人 |
ASTRAZENECA AB;ASTRAZENECA UK LIMITED;CHANG, HUI-FANG;CHAPDELAINE, MARC;DEMBOFSKY, BRUCE, THOMAS;HERZOG, KEITH, JOHN;HORCHLER, CAREY;SCHMIESING, RICHARD, JON |
发明人 |
CHANG, HUI-FANG;CHAPDELAINE, MARC;DEMBOFSKY, BRUCE, THOMAS;HERZOG, KEITH, JOHN;HORCHLER, CAREY;SCHMIESING, RICHARD, JON |